The evolution of antiepileptic drugs for mood stabilization and their main mechanisms of action

References

• Regier DA, Boyd JH, Burke JD Jr etal One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch. Gen. Psychiatry 45(11), 977–986 (1988).
   Google Scholar
• Weissman MM, Bland RC, Canino GJ etal. Cross-national epidemiology of major depression and bipolar disorder. JAIVIA 276(4), 293–299 (1996).
   PubMed Web of Science ®Google Scholar
• Angst J, Gamma A. A new bipolar spectrum concept: a brief review. Bipolar Disarlers 4\(Suppl. 1), 11–14 (2002).
   Google Scholar
• •Good review of the broadened bipolar spectrum.
   Google Scholar
• Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. j Gun. Psychopharmacol 16(2 Suppl. 1), 4S-14S (1996).
   Google Scholar
• McElroy SL, Keck PE, Pope HG etal Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Ainj PFchiatry149(12), 1633–1644 (1992).
   PubMedGoogle Scholar
• Swann AC, Bowden CL, Morris D etal Depression during mania. Treatment response to lithium or divalproex. Arch. Gen. Psychiatry 54(1), 37–42 (1997).
   Google Scholar
• Cooke RG, Young LT, Levitt AJ et al Bipolar II: Not so different when morbidity excluded. excluded. Depression 3(3), 154–156 (1995).
   Google Scholar
• Bowden CL. Clinical correlates of therapeutic response in bipolar disorder. j Affect. Disarl 67(1-3), 257–265 (2001).
   PubMedGoogle Scholar
• Greil W, Ludwig-Mayerhofer W Erazo N eta]. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders — a randomised study. J. Affect. Disarl. 43(2), 151–161 (1997).
   Google Scholar
• Vestergaard P Treatment and prevention of mania: a Scandinavian perspective. Neutopsychopharmacology7(4), 249–259 (1992).
   PubMedGoogle Scholar
• Calabrese JR, Woyshville MJ. Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Ann. an. PTchiatry7(2), 103–112 (1995).
   Google Scholar
• Bourgeois ML, Hantouche EG, Akiskal HS. The Epiman and Epidep french studies of bipolarity. J. Bipolar Disarler 1(1), 13–19 (1997).
   Google Scholar
• Bowden CL, Calabrese JR, Sachs GS eta]. Lamotrigine in bipolar depression. APA Annual meeting abstracts, 244.1998. New Research.
   Google Scholar
• Calabrese JR, Bowden CL, Sachs GS et al A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression.' Clin. Psychiatry 60,79–88 (1999).
   PubMed Web of Science ®Google Scholar
• •First controlled study demonstarting the antidepressive efficacy of LTG in bipolar I patients.
   Google Scholar
• Mishory A, Yaroslavsky Y, Bersudsky Y etal Phenytoin as an antimanic anticonvulsant: a controlled study. Am. J. Psychiatry 157(3), 463–465 (2000).
   Google Scholar
• Chouinard G. Clonazepam in acute and maintenance treatment of bipolar affective disorder. J. Clin. Psychiatry48(Suppl.), 29–37 (1987).
   Google Scholar
• Bradwejn J, Shriqui C, Koszycki D et al Double-blind comparison of the effects of donazepam and lorazeparn in acute mania. Clin. Bychophalmacol 10(6), 403–408 (1990).
   PubMedGoogle Scholar
• Edwards R, Stephenson U, Hewett T Clonazepam in acute mania: a double-blind trial. Aust. NZI. PTchiatry25(2), 238–242 (1991).
   Google Scholar
• Bottai T, Hue B, Hillaire-Buys D eta]. Clonazepam in acute mania: time-blind evaluation of clinical response and concentrations in plasma. J. Affect. Disord 36(1–2), 21–27 (1995).
   Google Scholar
• Chouinard G, Annable L, Tumier L etal A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can. J. fiychiatry38 (Suppl. 4), S114—S121 (1993).
   Google Scholar
• Sachs GS, Weilburg JB, Rosenbaum JE Clonazepam vs. neuroleptics as adjuncts to lithium maintenance. Rychopharmacol Bull. 26(1), 137–143 (1990).
   PubMedGoogle Scholar
• Aronson TA, Shukla S, Hirschowitz J. Clonazepam treatment of five lithium-refractory patients with bipolar disorder. Ainj Psychiatry 146(1), 77–80 (1989).
   PubMedGoogle Scholar
• Weiss SR, Post RM. Kindling: separate vs. shared mechanisms in affective disorders and epilepsy. Neuropsychobiology 38(3), 167–180 (1998).
   PubMedGoogle Scholar
• Post RM, Ketter TA, Denicoff K et al The place of anticonvulsant therapy in bipolar illness. PTchophalmacology128(2), 115–129 (1996).
   PubMedGoogle Scholar
• Keck PE, McElroy SL. Outcome in the pharmacologic treatment of bipolar disorder. .1. Clin. PTchophalmacol. 16(2 Suppl. 1), 15S-23S (1996).
   Google Scholar
• Emrich HM. Studies with oxcarbazepine (Trileptal) in acute mania. Int. Clin. fiychopharmacol 5\(Suppl. 1), 83–88 (1990).
   Google Scholar
• Muller AA, Stoll K-D. Carbamazepine and oxcarbamazepine in the treatment of manic syndromes: studies in Germany. In: Anticonvulsants in Affective Disorrlers: Emrich HM, Okuma T, Muller AA (Eds). Amsterdam, The Netherlands, 139–147 (1984).
   Google Scholar
• Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry 34 (6), 242–250 (2001).
   PubMed Web of Science ®Google Scholar
• Hummel B, Walden J, Stampfer R etal Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on- off-on design. Bipolar Disord In press.
   Google Scholar
• Alberto G, Erickson T, Popiel R etal Central nervous system manifestations of a valproic acid overdose responsive to naloxone. Ann. Emerg: Med. 18(8), 889–891 (1989).
   PubMedGoogle Scholar
• Lloyd P, Flesch G, Dieterle W Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35 (Suppl. 3), S10—S13 (1994).
   Google Scholar
• Cloyd J. Pharmacokinetic pitfalls of present anti-epileptic medications. Epilepsia 32\(Suppl. 5), S53—S65 (1991).
   Google Scholar
• Hesslinger B, Normann C, Langosch JM etal Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. j Clin. fiychopharmacol 19(4), 310–315 (1999).
   PubMed Web of Science ®Google Scholar
• Okuma T, Kishimoto A, Inoue K et al Antimanic and prophylactic effects of carbamazepine (Tegretoln on manic depressive psychosis. A preliminary report. Folia PTchiatr: Neural fpn 27(4), 283–297 (1973).
   PubMedGoogle Scholar
• Okuma T, Inanaga K, Otsuki S et al A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. PTchopharmacology 3erl.)73(1), 95–96 (1981).
   Google Scholar
• Hartong EGThM, Moleman P, Hoogduin CAL, Broekman TG, Nolen W Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. j Clin. Psychiatry (In press).
   Google Scholar
• Greil W, Kleindienst N, Erazo N etal Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. .1. Clin. fiychopharmacol 18,455–460 (1998).
   Google Scholar
• Denicoff KD, Smith-Jackson EE, Disney ER etal Comparative prophylactic efficacy of lithium, carbamazepine and the combination in bipolar disorder. J. Clin. Psychiatry58(11), 470–478 (1997).
   Google Scholar
• Maj M, Pirozzi R, Magliano L etal. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am. J. Psychiatry 155(1), 30–35 (1998).
   Google Scholar
• Frankenburg FR, Tohen M, Cohen BM et al Long-term response to carbamazepine: a retrospective study. Clin. Psychopharmacol 8(2), 130–132 (1988).
   PubMedGoogle Scholar
• Post RM. Prophylaxis of bipolar disorders. Int. Rev. Psychiatry 2,277–320 (1990).
   Google Scholar
• Kruger S, Braunig P, Young LT Biological treatment of rapid-cycling bipolar disorder. Pharmacopsychiatry29(5), 167–175 (1996).
   PubMedGoogle Scholar
• Okuma T Effects of carbamazepine and lithium on affective disorders. Neumpsychobiology27(3), 138–145 (1993).
   Google Scholar
• Grunze H, Amann B, Walden J. How might anticonvulsant drugs work in bipolar affective disorder? In: Seizures, Affective disarlers ancl Anticonvulsant drugs. Trimble MR, Schmitz B (Eds). Clarius Press, Guildford, UK, 117–130 (2002).
   Google Scholar
• Lambert PA, Venaud G. Utilisation de valpromide en therapeutique psychiatrique. Eencephale 8,367–373 (1966).
   Google Scholar
• Emrich HM, von Zerssen D, Kissling W et al Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch. Psychiatr: Nervenkr 229 (1), 1–16 (1980).
   Google Scholar
• Pope HG, McElroy SL, Keck PE etal Valproate in the treatment of acute mania. A placebo-controlled study. Arch. Gen. Psychiatry 48(1), 62–68 (1991).
   Google Scholar
• Freeman TVV, Clothier JL, Pazzaglia P etal A double-blind comparison of valproate and lithium in the treatment of acute mania. Am Psychiatry149(1), 108–111 (1992).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC etal Efficacy of divalproex vs. lithium and
   Google Scholar
• •• placebo in the treatment of mania. The Depakote Mania Study Group. JAIVIA 271(12), 918–924 (1994). Important investigation demonstrating efficacy of VPA in manic patients.
   Google Scholar
• Muller-Oerlinghausen B, Retzow A, Henn F et al Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania. A prospective, randomized, double-blind, placebo-controlled multicenter study. j Clin. P9rhopharmacol 20,195–203 (2000).
   Google Scholar
• McElroy SL, Keck PE. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can. j Psychiatry 38(3 Suppl. 2), S62—S66 (1993).
   Google Scholar
• McElroy SL, Keck PE, Stanton SP etal A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. j Clin. P9rhiatry57(4), 142–146 (1996).
   Google Scholar
• Keck PE, McElroy SL, Tugrul KC etal Valproate oral loading in the treatment of acute mania.j Clin. Psychiatry 54(8), 305–308 (1993).
   Google Scholar
• Bowden CL, Janicak PG, Orsulak P etal Relation of serum valproate concentration to response in mania. Am j Psychiatry 153(6), 765–770 (1996).
   PubMed Web of Science ®Google Scholar
• Grunze H, Erfurth A, Amann B eta]. Intravenous valproate loading in acutely manic and depressed bipolar I patients. J. Clin. P9rhophalmacol. 19(4), 303–309 (1999).
   Google Scholar
• Schmidt D. Adverse effects of valproate. Epilepsia 25 (Suppl. 1), S44—S49 (1984).
   Google Scholar
• Grunze H, Walden J. Valpmat bei manisch- depressiven (bipolaten) Erktankungen. Thieme Verlag, Stuttgart, Germany (2000).
   Google Scholar
• Sachs GS, Printz DJ, Kahn DA etal The Expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med. Spec. Report 1–104 (2000).
   Google Scholar
• Grunze H, Kasper S, Goodwin G etal The World Federation of Societies of Biological Psychiatry (VVFSBP) Guidelines for the Biological Treatment of Bipolar Disorders. Part II: Treatment of Mania. World Biol. Psychiatry (In press).
   Google Scholar
• Zarin D, Pincus HA, McIntyre JS. APA Practice Guideline For The Treatment Of Patients With Bipolar Disorder. www.psych.org/clin_res/pg_bipolancfm (2002).
   Google Scholar
• Winsberg ME, DeGolia SG, Strong CM etal Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. j Affect. Disord 67 (1-3), 207–212 (2001).
   Google Scholar
• Solomon DA, Keitner GI, Ryan CE et al Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review. j Clin. P9rhopharmacol 18(1), 38–49 (1998).
   Google Scholar
• Burks S, Kulkarni S. The safety and efficacy of divalproex in bipolar disorder: A retrospective analysis of maintenance treatment. Proc.APA Annual Meeting, NR 332. (1996).
   Google Scholar
• Calabrese JR, Rapport DJ, Kimmel SE etal Rapid cycling bipolar disorder and its treatment with valproate. Can. j Psychiatry 38(3 Suppl. 2), S57—S61 (1993).
   Google Scholar
• Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch. Gen. fiychiatry 30(2), 229–233 (1974).
   Google Scholar
• •Showed that lithium is less effective in patients with four or more affective episodes and therefore the term 'rapid cycling' was created.
   Google Scholar
• Bowden CL, Calabrese JR, McElroy SL etal A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of out-patients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen Psychiatry 57,481–489 (2000).
   Google Scholar
• •Interesting investigation with the result that lithium as well as VPA is not superior to placebo in prophylactic treatment.
   Google Scholar
• Grunze H, von Wegerer J, Greene RVV etal Modulation of calcium and potassium currents by lamotrigine. Neumpsychobiology 38(3), 131–138 (1998).
   PubMed Web of Science ®Google Scholar
• Walden J, Hesslinger B, van Calker D etal Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Phalmacopsychiatry 29(5), 193–195 (1996).
   PubMedGoogle Scholar
• Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am j Psychiatry153(9), 1236 (1996).
   PubMed Web of Science ®Google Scholar
• Fogelson DL, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. j Clin. fiychiatry58(6), 271–273 (1997).
   Google Scholar
• Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. j Clin. P9rhopharmacol 17(3), 185–189 (1997).
   Google Scholar
• Kusumakar V, Yatham LN. Lamotrigine treatment of rapid cycling bipolar disorder. Am Psychiatry154(8), 1171–1172 (1997).
   PubMedGoogle Scholar
• Fatemi SH, Rapport DJ, Calabrese JR etal Lamotrigine in rapid-cycling bipolar disorder. I Clin. PFhiatry 58 (12), 522–527 (1997).
   Google Scholar
• Obrocea GV, Dunn RM, Frye MA etal Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol. PFhiatry 51 (3), 253–260 (2002).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Suppes T, Bowden CL etal A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder. j Clin. Psychiatry 61,841–850 (2000).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, DeVeaugh- Geiss J etal Lamotrigine demonstrates long-term mood stabilization in manic patients. APA Annual meeting abstracts 2001, NR 403. (2001).
   Google Scholar
• Calabrese J, Bowden CL, Sachs G etal A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Depressed Patients with Bipolar I Disorder. JAIVIA In press (2002).
   Google Scholar
• •Important study with positive results of LTG in the prophylactic treatment of bipolar patients.
   Google Scholar
• Erfurth A, Walden J, Grunze H. Lamotrigine in the treatment of schizoaffective disorder. Neuropsychobiology 38(3), 204–205 (1998).
   PubMedGoogle Scholar
• Walden J, Grunze H. New Anticonvulsants in Bipolar Disorder: Lamotrigine, Gabapentin, Tiagabine. In: Seizures, Affective disorclers. and Anticonvulsant drugs. Trimble MR, Schmitz B (Eds). Clarius Press, Guildford, UK, 131–142 (2002).
   Google Scholar
• Pande AC, Crockatt JG, Janney CA etal Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2(3), 249–255 (2000).
   PubMedGoogle Scholar
• McElroy SL, Altshuler LL, Suppes T etal Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am. j Psychiatry 158(3), 420–426 (2001).
   Google Scholar
• Meldrum BS. Update on the mechanism of action of anti-epileptic drugs. Epilepsia 37\(Suppl. 6), S4-11 (1996).
   Google Scholar
• McElroy SL, Kmetz GE Keck PE. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. Abstr. XXIst CINP Congress, 281. (1998).
   Google Scholar
• Normann C, Langosch J, Schaerer LO et al Treatment of acute mania with topiramate. Am. PTchiatry156(12), 2014 (1999).
   PubMed Web of Science ®Google Scholar
• Grunze HC, Normann C, Langosch J etal. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design.j Clin. Psychiatry 62 (6), 464–468 (2001).
   Google Scholar
• Marcotte D. Use of topiramate, a new anti- epileptic as a mood stabilizer. J. Affect. Disord 50,245–251 (1998).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Suppes T, Keck PE eta]. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol. Psychiatry 47,1025–1033 (2000).
   Google Scholar
• Rosenfeld WE, Schaefer PA, Pace K. Weight loss patterns with topiramate therapy. Epilepsia 38\(Suppl. 3), 58 (1997).
   Google Scholar
• Marson AG, Kadir ZA, Hutton JL et al The new anti-epileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38(8), 859–880 (1997).
   PubMed Web of Science ®Google Scholar
• Jones MW Topiramate — safety and tolerability. Can. J. Neural. Sci. 25(3), S13—S15 (1998).
   Google Scholar
• Stephen LJ, Maxwell JE, Brodie MJ. Transient hemiparesis with topiramate. BE Med 318(7187), 845 (1999).
   PubMed Web of Science ®Google Scholar
• Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder. Am Psychiatry156(12), 2014–2015 (1999).
   PubMedGoogle Scholar
• Grunze H, Erfurth A, Marcuse A eta]. Tiagabine appears not to be efficacious in the treatment of acute mania. j Clin. Bychiatry60(11), 759–762 (1999).
   Google Scholar
• Suppes T, Chisholm, K., Dhavale D et al Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord an press).
   Google Scholar
• Carta MG, Hardoy MC, Grunze H eta]. The use of tiagabine in affective disorders. Pharmacopsychiatry35(1), 33–34 (2002).
   PubMedGoogle Scholar
• Hovinga CA. Levetiracetam: a novel anti- epileptic drug. Phalmacothempy21 (11), 1375–1388 (2001).
   PubMed Web of Science ®Google Scholar
• Noyer M, Gillard M, Matagne A eta]. The novel anti-epileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. j Pharmacol 286(2), 137–146 (1995).
   Google Scholar
• Klitgaard H, Matagne A, Gobert J eta]. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur Pharmacol 353(2-3), 191–206 (1998).
   PubMed Web of Science ®Google Scholar
• Georg MD, Klitgaard H. Inhibition of neuronal hypersynchrony in vitm differentiates levetiracetam from classical anti-epileptic drugs. Pharmacol Res. 42(4), 281–285 (2000).
   Google Scholar
• Hachad H, Ragueneau-Majlessi I, Levy RII. New anti-epileptic drugs: review ondrug interactions. Ther. Drug- Monit. 24(1), 91–103 (2002).
   PubMed Web of Science ®Google Scholar
• Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9(2), 80–87 (2000).
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Burdick KE. Levetiracetam for acute mania. A117. Bychiatry159(1), 148 (2002).
   Google Scholar
• Walden J, Langosch J, Born C eta]. Levetiracetam and ethosuximide in the treatment of acute mania in an open study with an on-off-on design. Bipolar Disord 4 (Suppl. 1), 114 (2002).
   Google Scholar
• Kanba S, Yagi G, Kamijima K eta]. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Frog. Neuropsychopharmacol Bid Psychiatry 18(4), 707–715 (1994).
   Google Scholar
• Tober C, Rostock A, Rundfeldt C eta]. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur j Pharmacol 303(3), 163–169 (1996).
   Google Scholar
• Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am. Bychiatry 155(1), 12–21 (1998).
   PubMed Web of Science ®Google Scholar
• Shukla S, Godwin CD, Long LE eta]. Lithium—carbamazepine neurotoxicity and risk factors. A117. I Psychiatry141(12), 1604–1606 (1984).
   Google Scholar
• Frye MA, Ketter TA, Leverich GS eta]. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study.j Clin. PTchiatry 61 (1), 9–15 (2000).
   Google Scholar
• •Interesting study showing the increasing use of combination therapy in affective disorders.
   Google Scholar
• Grunze H, Dobmeier M. Modul Therapie akuter Episoden. In: Wissbuch Bipolare Störungen in Deutschland. Deutsche Gesellschaft far Bipolare Störungen e.V.(DGBS e.V.) (Ed.). CP-Verlag, Hamburg, Germany, 57–66 (2002).
   Google Scholar
• Kupka RVV, Nolen WA, Altshuler LL eta]. The Stanley Foundation Bipolar Network: 2. Preliminary summary of demographics, course of illness and response to novel treatments. Br. Bychiatry178 (41), S177—S183 (2001).
   Google Scholar
• Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. Clin. Psychiatry63(2), 146–151 (2002).
   PubMed Web of Science ®Google Scholar
• Suppes T, Leverich GS, Keck PE eta]. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients . I Affect. Disord 67 (1–3), 45–59 (2001).
   Google Scholar
• Dittmann S, Biedermann NC, Grunze H eta]. The Stanley Foundation Bipolar Network: Results of the naturalistic follow-up study (NFS) after 2 Vz years of follow-up in the German centres. Neuropsychobiology an press).
   Google Scholar
• Stoll AL, Severus WE. Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes. Harv. Rev. Psychiatry 4(2), 77–89 (1996).
   Google Scholar
• Yuan PX, Huang LD, Jiang YM eta]. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Bid Chem. 276(34), 31674–31683 (2001).
   Google Scholar
• Chen G, Huang LD, Zeng WZ eta]. Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability. Int. J. Neuropsychopharmacol 4 (1), 47–64 (2001).
   Google Scholar
• Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers. BE J. PFchiatry178 (Suppl. 41), S107—S119 (2001).
   Google Scholar
• Soares JC, Chen G, Dippold CS eta]. Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study. Psychiatry Res. 95(2), 109–118 (2000).
   PubMedGoogle Scholar
• Bebchuk JM, Arfken CL, Dolan MS et al A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Airh. Gen. Psychiatry57 (1), 95–97 (2000).
   Google Scholar
• Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2(3), 217–236 (2000).
   PubMedGoogle Scholar
• Manji HK, Lenox RII. The nature of bipolar disorder. J. Gun. Psychiatry 61 (Suppl. 13), 42–57 (2000).
   Google Scholar
• Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol. PTchiatry48(8), 740–754 (2000).
   Google Scholar
• Manji HK, Moore GJ, Rajkowska G eta]. Neuroplasticity and cellular resilience in mood disorders. Mal Psychiatiy5 (6), 578–593 (2000).
   PubMedGoogle Scholar
• Williams RS, Cheng L, Mudge AW etal. A common mechanism of action for three mood-stabilizing drugs. Nature 417(6886), 292–295 (2002).
   PubMed Web of Science ®Google Scholar
• Grunze H. The search for the Holy Grail — the ideal mood stabilizer: fiction or future? In: WPA Series Evidence Experience in fiychiatry' — Bipolar disoider. Maj M, Akiskal H, Lopez-Ibor JJ etal (Eds) Wiley & Sons, Chichester, UK, 229–232 (2002).
   Google Scholar
• Pande AC, Pollack MH, Crockatt J eta]. Placebo-controlled study of gabapentin treatment of panic disorder. J. Gun. Psychopharmacol 20(4), 467–471 (2000).
   Google Scholar
• Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann. Gun. Bychiatry13(3), 141–146 (2001).
   Google Scholar
• Crane DL. APA book of abstracts 2002, report sessions No. 120, page 48.
   Google Scholar
• Lara ME. APA book of abstracts 2002, report sessions No. 121, page 49.
   Google Scholar
• Ghaemi SN, Sachs GS, Chiou AM etal Is bipolar disorder still underdiagnosed? Are antidepressants overutilized. J. Affect. Disonl. 52(1–3), 135–144 (1999).
   Google Scholar
• Solomon DA, Ryan CE, Keitner GI eta]. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I../ Gun. Psychiatry 58(3), 95–99 (1997). Affiliations
   Google Scholar